Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visit

Corbus says it has reached last patient last visit in its Phase 1b CANYON-1 trial of obesity drug CRB-913.

Topline results were not presented yet; data are expected in September 2026.

The study aims to show whether the once-daily oral therapy can support meaningful weight loss with tolerability suited for longer-term use.

Management positioned CRB-913 as a non-incretin alternative for patients who stop GLP-1 treatments due to side effects or limited benefit.

The company also highlighted preclinical findings suggesting lower brain exposure versus monlunabant, a potential differentiator for safety positioning.